2026 AACR Renal Cell Carcinoma Highlights

• June 17, 2026

Quantitative stability of MGMT promoter methylation in recurrent glioma and implications for temozolomide rechallenge

• by Henry Noren, Gabriella Pelofsky, Brianna Suffren, Laura Mittelman, Christine Yohn, Aminah Twyman, Christopher A. Febres-Aldana, Arevik Abramyan, Aparna Sertil, Randy S. D’Amico, Jonathan H. Sherman, Morana Vojnic

• September 16, 2026

Dana-Farber/Boston Children's Named the Top Pediatric Cancer Program in the Nation for 2026-2027

U.S. News & World Report has recognized Dana-Farber/Boston Children’s Cancer and Blood Disorders Center as the #1 pediatric cancer program in the nation in its 2026-2027 Best Children’s Hospitals report.

• by

• September 15, 2026

• 3 min

The evolution of RTOG and NRG Oncology CNS tumors clinical trials

• by Kavita Sehrawat, Mei-Yin C. Polley, Michael A. Vogelbaum, Mark Gilbert, Arnab Chakravarti, Daniel P. Cahill, Andrew B. Lassman, David R. Raleigh, Erik P. Sulman, Mitch Machtay, Quynh Thu Le, Walter Curran, Vinai Gondi, Minesh P. Mehta

• September 15, 2026